Masimo Co. (NASDAQ:MASI – Get Free Report)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $96.66 and last traded at $96.88, with a volume of 26306 shares changing hands. The stock had previously closed at $97.03.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on MASI. Raymond James lowered their price target on shares of Masimo from $198.00 to $142.00 and set an “outperform” rating on the stock in a report on Thursday, August 10th. Stifel Nicolaus cut shares of Masimo from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $205.00 to $120.00 in a report on Tuesday, July 18th. Wells Fargo & Company decreased their price objective on shares of Masimo from $126.00 to $110.00 and set an “equal weight” rating for the company in a report on Wednesday, August 9th. StockNews.com cut shares of Masimo from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $136.00 price objective on shares of Masimo in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $141.57.
View Our Latest Analysis on Masimo
Masimo Price Performance
Masimo (NASDAQ:MASI – Get Free Report) last released its earnings results on Tuesday, August 8th. The medical equipment provider reported $0.62 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.24). The firm had revenue of $455.30 million for the quarter, compared to analyst estimates of $478.27 million. Masimo had a return on equity of 15.79% and a net margin of 5.30%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.35 EPS. On average, equities analysts anticipate that Masimo Co. will post 3.45 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its position in Masimo by 12.7% during the 2nd quarter. Barclays PLC now owns 48,952 shares of the medical equipment provider’s stock worth $8,055,000 after acquiring an additional 5,502 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its position in shares of Masimo by 10.3% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 8,537 shares of the medical equipment provider’s stock valued at $1,405,000 after buying an additional 797 shares during the last quarter. Orion Portfolio Solutions LLC acquired a new position in shares of Masimo during the second quarter valued at about $1,083,000. Wells Fargo & Company MN raised its position in shares of Masimo by 117.7% during the second quarter. Wells Fargo & Company MN now owns 33,262 shares of the medical equipment provider’s stock valued at $5,473,000 after buying an additional 17,983 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Masimo during the second quarter valued at about $226,000. Institutional investors and hedge funds own 85.96% of the company’s stock.
About Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
Recommended Stories
- Five stocks we like better than Masimo
- Space Investment: How to Invest in Space Exploration
- 3 Reasons This Sleeping Giant Is About To Wake Up
- How to Invest in Semiconductors
- MarketBeat Week in Review – 9/18 – 9/22
- How to Build Wealth with the Dividend Aristocrat Index
- 52-week Low Names To Tip The Upside Scale In Your Favor
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.
